LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE
    3.
    发明申请
    LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE 审中-公开
    ALPHA-ADRENOCEPTORS,DOPAMINE,HISTAMINE,IMIDAZOLINE和SEROTONIN受体的配体及其用途

    公开(公告)号:US20110039825A1

    公开(公告)日:2011-02-17

    申请号:US12810013

    申请日:2008-12-19

    摘要: The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously α-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C1-C4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, CF3, CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH2)m group, optionally substituted CH═CH group, optionally substituted CH2—CH═CH group, C≡C group, SO2 group; n=1, 2; m=1, 2, 3; solid line accompanied by dotted line, i.e. may represent single or double bond. The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients; to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.

    摘要翻译: 本发明涉及其具有广谱生物活性的新配体,其包括同时α-肾上腺素受体,多巴胺受体,组胺受体,咪唑啉受体和5-羟色胺受体,其中5-羟色胺5-HT 7受体是通式1的化合物,其形式为 游离碱,几何异构体,外消旋混合物或单独的光学异构体,药学上可接受的盐和/或水合物,其中:R1是氨基的取代基,其选自氢,任选取代的C 1 -C 4烷基,酰基,杂环基,烷氧基羰基,取代的 磺酰基 R2是选自氢,卤素,任选取代的C 1 -C 4烷基,CF 3,CN,烷氧基,烷氧基羰基,羧基,杂环基或取代的磺酰基的环状体系的取代基。 Ar是任选取代的芳基,不一定与杂环基或任选取代的芳族杂环基取代; W是任选取代的(CH 2)m基团,任选取代的CH = CH基团,任选取代的CH 2 -CH = CH基团,C≡C基团,SO 2基团; n = 1,2; m = 1,2,3。 伴有虚线的实线即可表示单键或双键。 本发明还涉及活性成分,包含所述配体作为活性成分的药物组合物; 用于治疗人类和温血动物的中枢神经系统(CNS)的疾病和病症的新型药物。

    LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF
    6.
    发明申请
    LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF 审中-公开
    5-HT6受体的配体,药物组合物,其生产和使用方法

    公开(公告)号:US20110046368A1

    公开(公告)日:2011-02-24

    申请号:US12741006

    申请日:2007-11-15

    摘要: The invention relates to novel ligands of 5-HT6 receptor, to a pharmaceutical composition containing said novel ligands of 5-HT6 receptor as active component and to novel medicaments used for humans and warm-blooded animals for treating diseases and conditions of central nervous system, in pathogenesis of which neuromediator systems induced by 5-HT6 receptors are playing an essential role.Azaheterocyclic compounds of the general formula 1 or racemates, or optical or geometrical isomers, or pharmaceutically acceptable salts and/or hydrates thereof are used as 5-HT6 ligands. Wherein R2 and R3 independently of each other represent an amino group substituent selected from hydrogen; substituted carbonyl; substituted aminocarbonyl; substituted aminothiocarbonyl; substituted sulphonyl; C1-C5-alkyl optionally substituted by: C6-C10-arylaminocarbonyl, heterocyclyl, C6-C10-arylaminocarbonyl, C6-C10-arylaminothiocarbonyl, C5-C10-azaheteroaryl, optionally substituted carboxyl, nitryl group, optionally substituted aryl; R1k represents from 1 to 3 substituents of cyclic system, independent of each other and selected from hydrogen, optionally substituted C1-C5-alkyl, C1-C5-alkoxy, C1-C5-alkenyl, C1-C5-alkynyl, halogen, trifluoromethyl, CN-group, carboxyl, optionally substituted aryl, optionally substituted heterocyclyl, substituted sulfonyl, optionally substituted carboxyl; the solid line accompanied by the dotted line represents a single or a double bond; n=1, 2 or 3.

    摘要翻译: 本发明涉及含有5-HT 6受体作为活性成分的所述新型配体的药物组合物和用于人和用于治疗中枢神经系统疾病和病症的温血动物的新型药物的5-HT 6受体的新配体, 在5-HT6受体诱导的神经调节因子的发病机理中起着重要的作用。 通式1的氮杂环化合物或其外消旋体或光学或几何异构体或其药学上可接受的盐和/或水合物用作5-HT 6配体。 其中R2和R3彼此独立地表示选自氢的氨基取代基; 取代羰基; 取代的氨基羰基; 取代的氨基硫代羰基; 取代磺酰基; 任选被C 6 -C 10芳基氨基羰基,杂环基,C 6 -C 10 - 芳基氨基羰基,C 6 -C 10 - 芳基氨基硫代羰基,C 5 -C 10 - 氮杂杂芳基,任选取代的羧基,硝基,任选取代的芳基取代的C 1 -C 5 - 任选取代的C 1 -C 5 - 烷基,C 1 -C 5 - 烷氧基,C 1 -C 5 - 烯基,C 1 -C 5 - 炔基,卤素,三氟甲基, CN-基团,羧基,任选取代的芳基,任选取代的杂环基,取代的磺酰基,任选取代的羧基; 伴随虚线的实线表示单键或双键; n = 1,2或3。